Odyssey Therapeutics

At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine. In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/

https://www.odysseytx.com/

51-200 employees

Growth Trajectory

Odyssey Therapeutics is poised for growth through its focus on developing precision immunomodulators and advancing its pipeline of clinical- and research-stage programs. The company's strategic collaboration with Terray Therapeutics and the expansion of its therapeutic modalities through AI/ML indicate a commitment to innovation and market expansion. Continued investment in its proprietary tools and platforms should allow them to efficiently build out a broad portfolio of product candidates.

Technical Challenges

Addressing the fundamental limitations of current autoimmune and inflammatory disease treatments.

Solving incredibly hard challenges in drug discovery.

Targeting historically challenging targets for autoimmune and inflammatory diseases.

Mitigating cytokine redundancy.

Managing complex therapeutic challenges in immunobiology.

Reconstituting functional transcription factors.

Tech Stack

Small molecule therapeuticsProtein therapeuticsAI/ML platformsNatural productsCovalent chemistry platformsImmunobiologyMedicinal chemistryComputational chemistryStructural biologyGeneticsPharmacologytNova drug discovery platform (Terray)Ultra-miniaturized chemistry platform (Terray)WordPress

Team Size

Executive Vice President and Head of Small Molecule Research

CFO

Board of Directors

Scientific Advisory Board

Drug discovery and development teams across multiple sites (Boston, Ann Arbor, and Frankfurt)

Key Risks

Competition from existing therapies targeting adaptive immune responses may limit market share.

The need to navigate regulatory approval processes for novel therapeutic modalities.

The possibility of clinical trial failures could impact the development pipeline.

The need to mitigate immunosuppressive risks associated with immunomodulatory therapies.

Challenges in scaling up production of both small molecule and protein therapeutics.

Opportunities

Addressing unmet needs in inflammatory and autoimmune diseases by focusing on upstream immune responses.

Leveraging AI/ML platforms to accelerate drug discovery and development.

Expanding the pipeline through strategic collaborations and internal innovation.

Developing combination therapies to enhance treatment efficacy and durability.

Capitalizing on the potential of first-in-class transcription factor therapies developed with Terray Therapeutics.

Live Data Stream

Access Our Live VC Funding Database

30,000+ funded startups

tracked in the last 3 months

B2B verified emails

of key decision makers

Growth metrics

Real-time company performance data

Live updates

of new VC funding rounds

Advanced filters

for sophisticated queries

API access

with multiple export formats

Access Database

Updated every 5 minutes